{"organizations": [], "uuid": "16dfca5c940fccbae134a966f908dda94a292aeb", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180502.html", "section_title": "Archive News &amp; Video for Wednesday, 02 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/idUSL8N1S90PC", "country": "US", "domain_rank": 408, "title": "BRIEF-Noxxon Pharma Says Will Need Significant Additional Funds To Conduct Its Future Clinical Trials", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 1.0, "site_type": "news", "published": "2018-05-02T14:00:00.000+03:00", "replies_count": 0, "uuid": "16dfca5c940fccbae134a966f908dda94a292aeb"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/idUSL8N1S90PC", "ord_in_thread": 0, "title": "BRIEF-Noxxon Pharma Says Will Need Significant Additional Funds To Conduct Its Future Clinical Trials", "locations": [], "entities": {"persons": [{"name": "noxxon", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 2 (Reuters) - NOXXON PHARMA:\n* ANNOUNCED ON MONDAY THAT ITS FY REVENUE WAS € NIL FOR 2017 COMPARED TO € 83 THOUSAND FOR 2016\n* FY LOSS FROM OPERATIONS 4.7 MILLION EUROS VS LOSS 8.6 MILLION EUROS\n* NET LOSS – ATTRIBUTABLE TO OWNERS OF CO 5.4 MILLION EUROS VS LOSS 10.7 MILLION EUROS\n* SAYS TO CONDUCT ALL CLINICAL TRIALS THAT IT WOULD LIKE TO EXECUTE IN COMING THREE YEARS, WILL NEED SIGNIFICANT ADDITIONAL FUNDS\n* SAYS MANAGEMENT IS PURSUING VARIOUS FINANCING ALTERNATIVES TO MEET THE GROUP’S FUTURE CASH REQUIREMENTS\n* SAYS ALTERNATIVES INCLUDE SEEKING ADDITIONAL INVESTORS, PURSUING INDUSTRIAL PARTNERSHIPS, OR OBTAINING FURTHER FUNDING FROM EXISTING INVESTORS THROUGH ADDITIONAL FUNDING ROUNDS, PURSUING MERGER OR ACQUISITION\n* BASED ON OPTIONS AVAILABLE, MANAGEMENT IS CONFIDENT TO BE ABLE TO RAISE ADDITIONAL CAPITAL, PREFERABLY IN FORM OF EQUITY\n* NO FINANCING COMMITMENTS WERE RECEIVED BY THE COMPANY AS OF TODAY\nSource text: bit.ly/2w2aPLp\nFurther company coverage: (Gdynia Newsroom)\n ", "external_links": ["https://twitter.com/reuters", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "https://instagram.com/reuters/", "https://www.youtube.com/user/ReutersVideo", "https://bit.ly/2w2aPLp"], "published": "2018-05-02T14:00:00.000+03:00", "crawled": "2018-05-03T12:20:33.023+03:00", "highlightTitle": ""}